View Older Stories View More Recent Stories

May 12, 2022 08:00AM Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
May 10, 2022 04:01PM Halozyme Reports First Quarter 2022 Results
May 9, 2022 09:00AM /R E P E A T -- Halo Collective Announces Preliminary Results for North Hollywood Dispensary and Sets Date for Westwood Dispensary Grand Opening/
May 7, 2022 03:00AM Halo Collective Announces Preliminary Results for North Hollywood Dispensary and Sets Date for Westwood Dispensary Grand Opening
May 3, 2022 02:20PM Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call
May 2, 2022 10:17AM Halo Collective Announces Filing of Halo Tek Prospectus and Change in Chief Financial Officer and Board of Directors
May 2, 2022 08:30AM /R E P E A T -- Westwood Budega™️ Receives State Permit and Prepares for Opening in May/
Apr 30, 2022 03:57AM Westwood Budega™️ Receives State Permit and Prepares for Opening in May
Apr 28, 2022 09:20AM Halo Collective Signs a Letter of Intent to Acquire Phytocann Group, a Leading European Wellness CBD Company
Apr 28, 2022 03:00AM Halo Collective Signs a Letter of Intent to Acquire Phytocann Group, a Leading European Wellness CBD Company
Apr 26, 2022 08:00AM HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA
Apr 13, 2022 06:00AM Halozyme Therapeutics (HALO) Acquires Antares Pharma (ATRS) for $5.60/sh or $960M
Apr 13, 2022 06:00AM Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Apr 12, 2022 04:40PM Halo Collective Announces Westwood Dispensary Completion, Local Inspections Passed, and Planned Opening for Second Budega™ in California
Apr 1, 2022 08:30AM Halo Collective Reports 63% Revenue Growth and 345% Cannabis Sales Volume Growth in the Fourth Quarter of 2021
Mar 24, 2022 08:01AM Halozyme Therapeutics (HALO) Enters Global Collaboration and License Agreement for ENHANZE with Chugai Pharmaceutical
Mar 24, 2022 08:00AM Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology
Mar 22, 2022 02:15AM Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis
Mar 16, 2022 09:00AM /R E P E A T -- Halo Collective Congratulates Akanda Corp. on Successful First Day of Nasdaq Trading/
Mar 16, 2022 02:00AM Halo Collective Congratulates Akanda Corp. on Successful First Day of Nasdaq Trading
Mar 15, 2022 04:02PM Halozyme Therapeutics (HALO) Appoints Moni Miyashita to its Board
Mar 15, 2022 04:01PM Halozyme Appoints Moni Miyashita to Board of Directors
Mar 14, 2022 08:12PM Akanda Corp. Announces Pricing of Initial Public Offering and Expects To Commence Trading on NASDAQ Tomorrow
Feb 28, 2022 08:30AM /R E P E A T -- Halo Collective Receives All Approvals for Budega™ Dispensary in North Hollywood, California/
Feb 25, 2022 05:26PM Halo Collective Receives All Approvals for Budega™ Dispensary in North Hollywood, California
Feb 22, 2022 04:01PM HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS
Feb 9, 2022 08:00AM HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL
Feb 2, 2022 04:43PM Halozyme Therapeutics (HALO) Appoints Nicole LaBrosse as New CFO
Feb 2, 2022 04:43PM Halozyme Appoints New Chief Financial Officer
Jan 10, 2022 08:00AM HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK
Jan 4, 2022 08:00AM Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference
Dec 13, 2021 04:05PM HALOZYME APPOINTS NEW GENERAL COUNSEL
Dec 9, 2021 04:01PM Halozyme Therapeutics (HALO) approves $750M share repurchase program
Dec 9, 2021 04:01PM HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM
Dec 1, 2021 02:30PM Halozyme (HALO) Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO in Combination with Carfilzomib and Dexamethasone for Patients with MM After First or Subsequent Relapse
Dec 1, 2021 02:21PM Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma Aft
Nov 30, 2021 05:10PM Halo Collective Confirms Stock Symbol Reverts Back to HCANF
Nov 18, 2021 09:00AM Halozyme to Present at Upcoming Investor Conferences
Nov 2, 2021 04:01PM Halozyme Reports Third Quarter 2021 Results
Oct 19, 2021 04:05PM Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call
Sep 15, 2021 04:05PM Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Aug 26, 2021 09:00AM Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference
Aug 9, 2021 04:01PM Halozyme Reports Second Quarter 2021 Results
Jul 30, 2021 08:00AM Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference
Mar 22, 2021 08:00AM NEO Exchange Announces Inclusion in FTSE Russell Indexes
Nov 23, 2020 08:05AM Horizon Therapeutics (HZNP) and Halozyme Therapeutics (HALO) Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Sep 7, 2020 04:23PM Halo Enters Partnership with FlowerShop* and G-Eazy
Apr 20, 2020 05:51PM Halo Announces Proposed Partnership with FlowerShop* and G-Eazy
View More Recent Stories View Older Stories